Webinar Summary/Description
Like other solid tumors, pancreatic cancer is in urgent need of more effective therapies. PET imaging using biomarkers such as CA19.9 is being explored as a means to improve treatment of pancreatic cancer by providing more information on tumor sizes and locations. PET imaging benefits from the use of antibody fragments that rapidly and selectively home to the tumor. While production of full-length antibodies for clinical applications is a mature technology, cGMP production of clinical grade antibody fragments remains challenging.
In this webinar, we present a detailed case study showing how affinity chromatography was first used to study a recombinant anti CA19.9 F(ab′)2 antibody fragment, but with limited success due to its inability to discriminate between F(ab′)2 and contaminating Fab fragments. A non-affinity based purification method using ion-exchange and mixed-mode resins eventually yielded the required purity. Tips on method development incorporating specific chemistries and a smooth integration into cGMP compatible process workflow will be discussed.
In this webinar you will learn about:
- Advantages of using ion-exchange and mixed-mode resins
- Optimizing a recombinant F(ab)2 antibody fragment purification process
- Method development for cGMP process workflow
- Technical limits of affinity chromatography
Who should attend:
- Protein purification researchers
- Discovery and process development scientists
- Researchers using chromatography
- Clinical and therapeutic researchers